Medicine
Ilaris 150 mg/1 mL injection
Ilaris 150 mg/1 mL injection is a prescription medicine containing Canakinumab for subcutaneous use, marketed by Novartis Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store in the original carton to protect from light.
Key facts
- Active ingredient (INN)
- Canakinumab
- Brand
- Ilaris
- Strength
- 150 mg/1 mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 1 vial of 1 mL
- Marketing authorisation holder
- Novartis Pharmaceuticals
- Manufacturer
- Novartis Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store in the original carton to protect from light.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L04AC08 Canakinumab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 22 December 2016
- Identifiers
- RxCUI 1864324, 1864326DailyMed set ID 7d271f3b-e4f9-4d80-8dcf-28d49123f80eNDC 0078-0734Application BLA125319
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, single-use in 1 carton / 1 mL in 1 vial, single-use | 0078-0734-61 | Novartis Pharmaceuticals | 22 December 2016 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Canakinumab is a prescription medicine indicated for the treatment of periodic Fever Syndromes, among other approved uses. It is available as injection for subcutaneous use. MedsAcross supplies Canakinumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about CanakinumabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Ilaris prescribing information (Novartis Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Ilaris: European public assessment report (EPAR) · European Medicines Agency
Need Ilaris 150 mg/1 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.